Importance of the Keap1-Nrf2 Pathway in NSCLC: Is It a Possible Biomarker?

Overview

Journal Biomed Rep

Specialty Biochemistry

Date 2018 Oct 23

PMID 30345037

Citations 23

Authors

Raul Barrera-Rodriguez

Affiliations

Soon will be listed here.

Abstract

Worldwide, lung cancer remains the most common cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for 85% of all diagnosed lung cancer cases. Chemotherapy is considered the standard of care for patients with advanced NSCLC; however, the tumors can develop mechanisms that inactivate these drugs. Comparative genomic analyses have revealed that disruptions in the kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid-2-related factor-2 (Nrf2) pathway are frequent in NSCLC, although Nrf2 mutations occur less frequently than Keap1 mutations. As the Keap1-Nrf2 pathway appears to be a primary regulator of key cellular processes that aid to resist the action of chemotherapy drugs, the clinical implementation of Nrf2 inhibitors in patients with advanced NSCLC may be a useful therapeutic approach for patients harboring KEAP1-NRF2 mutations. The aim of the present review was to highlight findings of how constitutive Nrf2 activation may be a specific biomarker for predicting patients most likely to benefit from classical chemotherapy drugs, overall improving patient survival rate.

Citing Articles

Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma.

Hsu C, Kao S, Yen C, Hsiao C, Cho S, Wang H Oncol Lett. 2024; 29(1):30.

PMID: 39512504 PMC: 11542154. DOI: 10.3892/ol.2024.14776.

Prevalence and Associations of Co-occurrence of Mutations and Chromosome 3q26 Amplification in Lung Cancer.

Liu J, Liu S, Li D, Li H, Zhang F Glob Med Genet. 2024; 11(2):150-158.

PMID: 38628662 PMC: 11018393. DOI: 10.1055/s-0044-1786004.

Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance.

Malik S, Sikander M, Wahid M, Dhasmana A, Sarwat M, Khan S Cancer Metastasis Rev. 2024; 43(3):981-999.

PMID: 38498072 DOI: 10.1007/s10555-024-10177-8.

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.

Nadal E, Saleh M, Aix S, Ochoa-de-Olza M, Patel S, Antonia S BMC Cancer. 2023; 23(1):708.

PMID: 37507657 PMC: 10386782. DOI: 10.1186/s12885-023-11153-1.

Black tea bioactive phytoconstituents realign NRF2 for anticancer activity in lung adenocarcinoma.

Datta S, Bishayee A, Sinha D Front Pharmacol. 2023; 14:1176819.

PMID: 37305533 PMC: 10247968. DOI: 10.3389/fphar.2023.1176819.

References

Jacobsen K, Bertran-Alamillo J, Molina M, Teixido C, Karachaliou N, Pedersen M . Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun. 2017; 8(1):410. PMC: 5583255. DOI: 10.1038/s41467-017-00450-6. View

Abed D, Goldstein M, Albanyan H, Jin H, Hu L . Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharm Sin B. 2015; 5(4):285-99. PMC: 4629420. DOI: 10.1016/j.apsb.2015.05.008. View

Shibata T, Ohta T, Tong K, Kokubu A, Odogawa R, Tsuta K . Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A. 2008; 105(36):13568-73. PMC: 2533230. DOI: 10.1073/pnas.0806268105. View

. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489(7417):519-25. PMC: 3466113. DOI: 10.1038/nature11404. View

Nioi P, Nguyen T . A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun. 2007; 362(4):816-21. DOI: 10.1016/j.bbrc.2007.08.051. View

Mahaffey C, Zhang H, Rinna A, Holland W, Mack P, Forman H . Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma. Free Radic Biol Med. 2009; 46(12):1650-7. PMC: 2692873. DOI: 10.1016/j.freeradbiomed.2009.03.023. View

Kim E . Chemotherapy Resistance in Lung Cancer. Adv Exp Med Biol. 2015; 893:189-209. DOI: 10.1007/978-3-319-24223-1_10. View

Taguchi K, Fujikawa N, Komatsu M, Ishii T, Unno M, Akaike T . Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc Natl Acad Sci U S A. 2012; 109(34):13561-6. PMC: 3427110. DOI: 10.1073/pnas.1121572109. View

Kim Y, Oh J, Kim M, Kang M, Park S, Han J . Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol. 2009; 220(4):446-51. DOI: 10.1002/path.2653. View

10.

Lu M, Ji J, Jiang Z, You Q . The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Med Res Rev. 2016; 36(5):924-63. DOI: 10.1002/med.21396. View

11.

Ichimura Y, Waguri S, Sou Y, Kageyama S, Hasegawa J, Ishimura R . Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell. 2013; 51(5):618-31. DOI: 10.1016/j.molcel.2013.08.003. View

12.

Seshacharyulu P, Ponnusamy M, Haridas D, Jain M, Ganti A, Batra S . Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16(1):15-31. PMC: 3291787. DOI: 10.1517/14728222.2011.648617. View

13.

Muscarella L, Parrella P, DAlessandro V, la Torre A, Barbano R, Fontana A . Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics. 2011; 6(6):710-9. DOI: 10.4161/epi.6.6.15773. View

14.

Bethune G, Bethune D, Ridgway N, Xu Z . Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2012; 2(1):48-51. PMC: 3256436. View

15.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

16.

Kinch L, Grishin N, Brugarolas J . Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell. 2011; 20(4):418-20. PMC: 3226726. DOI: 10.1016/j.ccr.2011.10.005. View

17.

Wang R, An J, Ji F, Jiao H, Sun H, Zhou D . Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun. 2008; 373(1):151-4. DOI: 10.1016/j.bbrc.2008.06.004. View

18.

Kobayashi A, Kang M, Okawa H, Ohtsuji M, Zenke Y, Chiba T . Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004; 24(16):7130-9. PMC: 479737. DOI: 10.1128/MCB.24.16.7130-7139.2004. View

19.

Scheel A, Ansen S, Schultheis A, Scheffler M, Fischer R, Michels S . PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. Oncoimmunology. 2016; 5(5):e1131379. PMC: 4910698. DOI: 10.1080/2162402X.2015.1131379. View

20.

Magesh S, Chen Y, Hu L . Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev. 2012; 32(4):687-726. PMC: 3393814. DOI: 10.1002/med.21257. View